Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102123207> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- W2102123207 endingPage "A311" @default.
- W2102123207 startingPage "A310" @default.
- W2102123207 abstract "To evaluate the cost-utility of CZP compared with standard-of-care first-line administered TNF-inhibitors + MTX in the treatment of moderate-to-severe RA in Spain. A Markov (cohort health state transition) model was developed to evaluate the cost-utility of CZP versus the other TNF-inhibitors licensed and recommended in Spain (etanercept [ETA], adalimumab [ADA], and infliximab [IFX]). Treatment efficacy was measured using ACR-responses (ACR20, ACR50 or ACR70) at 6 months. ACR estimated response rates were based on adjusted indirect comparison (MTX as the common comparator) of published clinical trials. Utilities were derived from EQ-5D data collected in CZP RA clinical trials. Clinical history and resource use data came from published literature. Unit costs (drug, administration, monitoring, and resources) were taken from Spanish routine sources or published references (cost year 2009). Base case analysis was conducted from the payer perspective, with a lifetime horizon, annual discounting rates of costs and outcomes of 3.5% and inflation rate for 2009 onwards of 3%. One-way sensitivity analyses were conducted. The average lifetime costs for CZP+MTX, ETA+MTX, ADA+MTX and IFX+MTX were €140,971, €141,197, €139,148 and €136,961, respectively. The quality-adjusted life-years (QALYs) gained were 6.578, 6.462, 6.430 and 6.318, respectively. The deterministic cost-effectiveness analysis found that CZP+MTX dominated ETA+MTX (lower cost, greater QALYs), and that CZP+MTX was cost-effective vs ADA+MTX and IFX+MTX at the €30,000/QALY willingness-to-pay threshold (ICERs of €12,346/QALY and €15,414/QALY, respectively). One-way sensitivity analyses showed that ICERs were most sensitive to the change in annual discount rates, the model cycle (evaluation of ACR response at 3 instead of 6 months), the analysis perspective and the estimation of utilities (HAQ-DI mapping instead of direct evaluation from EQ-5D). This analysis shows that CZP+MTX is cost-effective versus the other considered TNF-inhibitors recommended in Spain for the treatment of RA." @default.
- W2102123207 created "2016-06-24" @default.
- W2102123207 creator A5018291004 @default.
- W2102123207 creator A5019094000 @default.
- W2102123207 creator A5052241594 @default.
- W2102123207 creator A5066147863 @default.
- W2102123207 date "2011-11-01" @default.
- W2102123207 modified "2023-09-28" @default.
- W2102123207 title "PMS46 Cost-Utility Analysis of Certolizumab Pegol versus Alternative Tumor Necrosis Factor-Inhibitors, for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Spain" @default.
- W2102123207 doi "https://doi.org/10.1016/j.jval.2011.08.432" @default.
- W2102123207 hasPublicationYear "2011" @default.
- W2102123207 type Work @default.
- W2102123207 sameAs 2102123207 @default.
- W2102123207 citedByCount "2" @default.
- W2102123207 countsByYear W21021232072013 @default.
- W2102123207 countsByYear W21021232072015 @default.
- W2102123207 crossrefType "journal-article" @default.
- W2102123207 hasAuthorship W2102123207A5018291004 @default.
- W2102123207 hasAuthorship W2102123207A5019094000 @default.
- W2102123207 hasAuthorship W2102123207A5052241594 @default.
- W2102123207 hasAuthorship W2102123207A5066147863 @default.
- W2102123207 hasBestOaLocation W21021232071 @default.
- W2102123207 hasConcept C126322002 @default.
- W2102123207 hasConcept C143998085 @default.
- W2102123207 hasConcept C17991360 @default.
- W2102123207 hasConcept C2776215756 @default.
- W2102123207 hasConcept C2777575956 @default.
- W2102123207 hasConcept C2780132546 @default.
- W2102123207 hasConcept C3020084786 @default.
- W2102123207 hasConcept C71924100 @default.
- W2102123207 hasConceptScore W2102123207C126322002 @default.
- W2102123207 hasConceptScore W2102123207C143998085 @default.
- W2102123207 hasConceptScore W2102123207C17991360 @default.
- W2102123207 hasConceptScore W2102123207C2776215756 @default.
- W2102123207 hasConceptScore W2102123207C2777575956 @default.
- W2102123207 hasConceptScore W2102123207C2780132546 @default.
- W2102123207 hasConceptScore W2102123207C3020084786 @default.
- W2102123207 hasConceptScore W2102123207C71924100 @default.
- W2102123207 hasIssue "7" @default.
- W2102123207 hasLocation W21021232071 @default.
- W2102123207 hasOpenAccess W2102123207 @default.
- W2102123207 hasPrimaryLocation W21021232071 @default.
- W2102123207 hasVolume "14" @default.
- W2102123207 isParatext "false" @default.
- W2102123207 isRetracted "false" @default.
- W2102123207 magId "2102123207" @default.
- W2102123207 workType "article" @default.